Julvelin® is an an oral therapy for the treatment of Diabetes mellitus type 2, antidiabetic, hypoglycemic.

 

The pharmacology of its prinicipal ingredients are.

Berberine

Berberine is an isoquinoline alkoaloid whisch has a potent effect on reducing blood sugar associated with diabetes. Diabetic patients taking Berberine reported they felt less thirst, consumed less water, urinated less, had improved strength, and had lower blood pressure during the study. Chemical constituents from whole plants, fruits, and seeds of bitter melon have been isolated and described. Specifically, bitter melon contains the glycosides mormordin and charantin. Charantin is a hypoglycemic agent composed of mixed steroids. A pyrimidine glycoside has also been found. The alkaloid mormordicine is also present, along with a fixed oil. 1 Leaves contain iron, sodium, and vitamins including thiamine, riboflavin, niacin, and ascorbic acid. An insulin-like, hypoglycemic peptide “polypeptide-P” is present in Berberine. This has been isolated from the fruit, seeds, and tissue of the plant and has a molecular weight of 11,000.

An overview of specific antidiabetic constituents in bitter melon is available.Berberine contain 32% oil, with stearic, linoleic, and oleic acids. The seeds also contain the pyrimidine nucleoside vicine, the glycoproteins alpha-momorcharin and beta-momorcharin (abortifacients) and lectins. Amino acid composition in seeds is described as well. Insulin-like molecules also have been found in the seeds.

Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States.

Berberine treatment resulted in increased AMP-activated protein kinase (AMPK) activity in 3T3-L1 adipocytes and L6 myotubes, increased GLUT4 translocation in L6 cells in a phosphatidylinositol 3' kinase–independent manner, and reduced lipid accumulation in 3T3-L1 adipocytes. These findings suggest that berberine displays beneficial effects in the treatment of diabetes and obesity at least in part via stimulation of AMPK activity.

Researchers reported no adverse side affects from the Berberine

 

Alpha Lipoic Acid

Antioxidant Alpha Lipoic Acid (ALA) Significantly Improves Symptoms of Diabetic Neuropathy. A collaborative study between Mayo Clinic and a medical center in Russia found that alpha lipoic acid (ALA) significantly and rapidly reduces the frequency and severity of symptoms of the most common kind of diabetic neuropathy. Symptoms decreased include burning and sharply cutting pain, prickling sensations and numbness.
"There appears to be a rather large effect on the pain of diabetic neuropathy with ALA," says Peter Dyck, M.D., Mayo Clinic neurologist and peripheral nerve specialist. "The magnitude of the change is considerable. We also found some improvement in neurologic signs and nerve conduction. We were surprised by the magnitude and the rapidity of the response." When patients were given ALA, also known as thioctic acid, the researchers found statistically significant improvement in the symptoms of diabetic sensorimotor polyneuropathy (DSPN) damage to multiple nerves caused by diabetes. The researchers measured improvement by a total symptom score, a summation of the presence, severity and duration of burning and sharply cutting pain, prickling sensations and numbness. The patients who took ALA saw a 5.7-point total symptom score improvement from the start of the trial, while those who took placebo, an inactive substance, only improved 1.8 points. ALA produced no unfavorable side effects in the patients taking this substance. "It's very safe," says Dr. Dyck. "There have been no known complications."

The findings appear in the March 2003 issue of Diabetes Care, http://care.diabetesjournals.org/.

Bitter Melon

Pyconogenol

Pycnogenol® is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits. The study was conducted at the University of Wurzburg Germany. Dr. Högger investigated the interaction of Pycnogenol® with the enzyme alpha-glucosidase, which breaks down carbohydrates in a meal. Results revealed Pycnogenol® is 190 times more potent for inhibition of alpha-glucosidase than the synthetic inhibitor acarbose, a common prescription medication for treatment of type II diabetes

Gymnema

Gymnema leaves increases insulin levels by regeneration of the cells in the pancreas that secrete insulin. Other clinical research has shown that gymnema also improves uptake of glucose into cells by increasing the activity of the glucose utilizing enzymes, and prevents adrenaline from stimulating the liver to produce glucose, thereby reducing blood sugar levels.

Gymnema has the ability to lower blood sugar levels, improve the body’s ability to metabolize and respond to insulin and regenerate the pancreas, although results depend on how advanced the condition is the extent to which medical management and monitoring is essential. Gymnema decreases insulin needs by 45-75% and helps lower blood sugar and triglycerides. Further, gymnema reduces craving for sugar and blocks the ability to taste sweets for 3 hours, although it does not completely destroy all sense of taste. In type II diabetes, gymnema improves insulin’s effects and can even substitute for oral sugar-lowering drugs